Skip to main content

Table 4 Longitudinal 6–months interval change during pirfenidone treatment in FVC % of predicted (ΔFVC) and TLCO % of predicted (ΔTLCO). Data are presented as median (IQR) values

From: A multicentre retrospective observational study on Polish experience of pirfenidone therapy in patients with idiopathic pulmonary fibrosis: the PolExPIR study

 

0–6 months

6–12 months

12–18 months

18–24 months

p (6–12 vs 0–6)

p (12–18 vs 0–6)

p (18–24 vs 0–6)

∆FVC

0 (−3.69–3.93)

−1.06 (−3.90–2.90)

−1.84 (−5.04–1.37)

−2.10 (−5.73–1.63)

0.13

< 0.01

< 0.05

∆TLCO

−2.02 (−7.81–3.09)

−2.11 (−6.79–1.96)

−2.17 (−8.07–1,84)

−3.56 (−8.77–1.12)

0.98

0.24

0.22

  1. Abbreviations: FVC forced vital capacity, TLCO transfer factor of the lung for carbon monoxide
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us